ABIONYX Pharma Balance Sheet Health
Financial Health criteria checks 6/6
ABIONYX Pharma has a total shareholder equity of €9.4M and total debt of €1.4M, which brings its debt-to-equity ratio to 14.4%. Its total assets and total liabilities are €15.5M and €6.0M respectively.
Key information
14.4%
Debt to equity ratio
€1.36m
Debt
| Interest coverage ratio | n/a |
| Cash | €5.30m |
| Equity | €9.45m |
| Total liabilities | €6.01m |
| Total assets | €15.46m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 609's short term assets (€7.5M) exceed its short term liabilities (€3.3M).
Long Term Liabilities: 609's short term assets (€7.5M) exceed its long term liabilities (€2.7M).
Debt to Equity History and Analysis
Debt Level: 609 has more cash than its total debt.
Reducing Debt: 609's debt to equity ratio has reduced from 14.8% to 14.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 609 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 609 is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.